je.st
news
Home
› MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA (pembrolizumab) for Advanced Gastric Cancer
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA (pembrolizumab) for Advanced Gastric Cancer
2015-10-22 13:30:46| Merck.com - Product News
Dateline City: ROCKVILLE, Md. and KENILWORTH, N.J. Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer ROCKVILLE, Md.and KENILWORTH, N.J. Language: English read more
Tags: advanced
study
combination
cancer
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||